M.D. Paul A Friedman - 16 Jan 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Brian J. Lynch**
Issuer symbol
MDGL
Transactions as of
16 Jan 2023
Net transactions value
-$549,796
Form type
4
Filing time
18 Jan 2024, 13:47:11 UTC
Previous filing
22 Jun 2022
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Tax liability $549,796 -2,254 -10% $243.92 20,001 16 Jan 2023 Direct F1, F2
holding MDGL Common Stock 165,734 16 Jan 2023 Direct
holding MDGL Common Stock 655,540 16 Jan 2023 By SQN LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023.
F2 Represents restricted stock units granted to the Reporting Person on January 16, 2023.
F3 The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

**As attorney-in-fact for Reporting Person